# Lantheus Holdings, Inc. – Consensus ‘buy’ rating and 68.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/lantheus-holdings-inc.consensus-buy-rating-and-68.0-upside-potential-2/4121130227
- Published: 2023-10-20T12:42:38+01:00
- Author: Charlotte Edwards

**Lantheus Holdings, Inc.** which can be found using ticker (LNTH) have now 8 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between 130 and 100 calculating the mean target
price we have $118.38. Given that the stocks previous close was at $70.48 this would
imply there is now a potential upside of 68.0%. There is a 50 day moving average
of $67.10 and the 200 day MA is $75.49. The market cap for the company is 4.74B.
The stock price for the company is currently 69.21 USD

 The potential market cap would be $7,954,855,650 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 141.24, revenue per share of 16.46
and a 8.4% return on assets.

Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted
therapeutics, and artificial intelligence solutions to find, fight and follow serious
medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical
oncology, and strategic partnerships. Its precision diagnostic products assist healthcare
professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical
oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its
strategic partnerships focus on enabling precision medicine through the use of biomarkers,
digital solutions and pharma services platforms, and also includes the Company’s
license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products
are used by oncologists, urologists, nuclear medicine physicians, cardiologists,
sonographers, technologists, radiologists, and internal medicine physicians working
in a variety of clinical settings.

Share on: